Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products, has announced plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder (MDD). The trial is expected to begin in the first half of 2027, with dosing anticipated to be completed by year-end, according to a press release disseminated by NetworkNewsWire.
The Health Canada-authorized trial will enroll up to 200 participants across multiple Canadian sites. It will evaluate the safety and efficacy of a single supervised dose of Optimi's naturally derived psilocybin, which is manufactured at its GMP facility. The company will exclusively own the trial results and plans periodic interim safety and efficacy readouts, with full topline results following completion of dosing and follow-up evaluations. Optimi stated that the study represents an initial step toward potential registration and can be funded with current cash on hand.
This development is significant for the mental health industry as it marks a major step forward in the clinical evaluation of psychedelic-assisted therapies for depression, a condition that affects millions worldwide and often resists conventional treatments. If successful, the trial could pave the way for regulatory approval and broader access to psilocybin-based therapies, offering new hope for patients with MDD. For Optimi Health, the trial underscores its commitment to advancing psychedelic medicine and could strengthen its position in the emerging market for psychedelic pharmaceuticals.
Optimi Health Corp. is a Health Canada-licensed pharmaceutical manufacturer that produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. The company supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally. Its products are currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and are accessible in Canada through the Special Access Program. More information about the company is available at https://www.optimi.net/.
The trial's progress will be closely watched by investors, healthcare providers, and patients alike, as it could influence the future of depression treatment and the regulatory landscape for psychedelic therapies. With dosing expected to conclude by the end of 2027, the company anticipates periodic updates, keeping stakeholders informed of key milestones.
